BiotechTubeBiotechTube
Home/Kyowa Kirin/Masashi Miyamoto
MM

Masashi Miyamoto

President and Chief Executive Officer

Kyowa Kirin

Therapeutic Areas

Rare DiseasesOncologyImmunologyNephrologyHematology

Kyowa Kirin Pipeline

DrugIndicationPhase
Mogamulizumab (Poteligeo)Cutaneous T-cell lymphomaApproved
Burosumab (Crysvita)X-linked hypophosphatemiaApproved
Evocalcet (Orkedia)Secondary hyperparathyroidismApproved
KW-6356Atopic dermatitisPhase 2
MezagitamabB-cell malignanciesPhase 1/2
KHK4083Atopic dermatitisPhase 2
Romiplostim (Nplate)ThrombocytopeniaApproved
Darbepoetin alfaAnemiaApproved

Leadership Team at Kyowa Kirin

TY
Takeyoshi Yamashita
Executive Vice President
WM
Wataru Murata
Chief Financial Officer
YK
Yuki Kuroda
Senior Vice President, Corporate Strategy
NH
Nobuo Hanai
Chairman of the Board
MK
Motohiko Kawaguchi
Senior Vice President, R&D
View full Kyowa Kirin profile